Everfront Biotech Inc. Receives "Investor's Choice Award" at the 2023 NBRP Demo Day Investment Matchmaking Competition
Date: 2023/5/5
Everfront Biotech’s theme for this year’s competition was “Revolutionizing Brain Cancer Treatment with Cerebraca® Wafer,” which stood out and won the “Investor’s Favorite Award” at the NBRP Demo Day investment matchmaking competition. In a limited amount of time, Dr. Lee introduced Everfront Biotech’s research and development capabilities, the pharmacological mechanism, precise release characteristics, preliminary results from phase I clinical trials, and compared them with current treatment methods, all of which sparked a high level of interest and enthusiasm among the attending investors. This presentation led to Everfront Biotech Inc. being recognized by the investors and awarded the prize, which demonstrated their strong willingness to invest in Cerebraca® Wafer…
Our Team Is Honored with the National Innovation Award – Clinical Innovation for Treating Recurrent Malignant Brain Tumors
Date: 2022/12/6
Six years ago, commissioned by Everfront Biotech Inc., the team from Hualien Tzu Chi Hospital, in collaboration with the neurosurgery team from Tri-Service General Hospital, carried out clinical trials for the development of the new drug Cerebraca® wafer for the treatment of malignant brain tumors…
Everfront Biotech's Investigational product, Cerebraca® Wafer, has achieved significant progress in Phase I clinical trials for the treatment of malignant brain tumors, and has been invited to speak at the Asian Congress of Neurological Surgeons (ACNS).
Date: 2022/6/9
Hualien Tzu Chi Hospital collaborated with the neurosurgery team from Tri-Service General Hospital to conduct clinical trials for the development of a new drug, Cerebraca® Wafer, for the treatment of malignant brain tumors, under the leadership of the Superintendent, Dr. Shinn-Zon. Dr. Lin was invited by the President of the Asian Congress of Neurological Surgeons, Professor Yoko Kato, to share the results of the phase I clinical trial via video conference on June 8th at 8:30 PM.
Everfront Biotech's Cerebraca® Wafer has Completed the Phase I - Safety Evaluation for the Treatment of Glioblastoma Multiforme, and has Initiated the Phase IIa - Efficacy Evaluation
Date: 2022/4/29
Everfront Biotech Inc., a company focused on developing new drugs for over 20 years, specializing in cancer, neurodegenerative, and rare diseases, has developed a small molecule targeted therapy for glioblastoma multiforme called Cerebraca® Wafer. The drug will complete phase II trials at Hualien Tzu Chi Hospital, Taipei Tri-Service General Hospital, and Taichung Veterans General Hospital, and is preparing to publish its findings in the renowned international journal, Cancers. This breakthrough from a local Taiwanese research team has not only energized the medical community, but also prompted the company to seek international collaborations through an initial public offering.
The Research Team for Developing a New Drug, EF-009, for the Treatment of Pancreatic Cancer Won the National Innovation Award
Date: 2021/11/16
The preclinical development of EF-009 has been completed, and the process meets the international standards of PIC/S GMP for the production of active pharmaceutical ingredient, excipient, and drug product – Cerebraca® wafer. Results from toxicity studies, safety pharmacology studies, genotoxicity studies, and pharmacokinetic studies have preliminary confirmed its safety and drug metabolism characteristics.
This new drug has been transferred to Everfront Biotech Inc. and has received Investigational New Drug (IND) approval from the USFDA and the Taiwan FDA. It will soon enter Phase I/IIa trial to test its safety and efficacy in humans, with the hope of helping pancreatic cancer patients in the future.
Targeted Small Molecules can Enhance Treatment for Glioblastoma Multiforme, winning the National Innovation Award
Date: 2019/12/7
Superintendent Shinn-Zong Lin led the new drug innovation and development team to discover the targeted small molecule drug EF-001, which is used to inhibit the cancer immune checkpoint PD-L1, activate immune T cells, and enhance the immunotherapy effect of glioblastoma multiforme. This is a major breakthrough in global immunotherapy research for glioblastoma multiforme and has been recognized by the National Innovation Award with the “Academic Research and Innovation Award” …
"2019 Taipei Biotech Award": Ko Wen-Je Claims Biotech to be the Most Potential Industries
Date: 2019/7/26
“The 2019 Taipei Biotech Awards were divided into three categories: the New Technology Award, the International Breakthrough Award, and the Technology Transfer and Collaboration Award, with a total of 15 finalists. Action Gene took home the gold award in the New Technology category, receiving the highest prize of 1 million NTD. Taiwan Biotech Co. (6589) and Everfront Biotech Inc. were awarded the Excellence Award in the same category.”
Everfront Biotech Inc. and Buddhist Tzu Chi Hospital Jointly Develop New Drugs
Date: 2018/3/24
Everfront Biotech Inc. successfully completed its Phase I trial application at Buddhist Tzu Chi General Hospital in Hualien, Taiwan and Tri-Service General Hospital in Taipei, Taiwan. The clinical trial was initialed on December 25th, 2017, with the Superintendent, Dr. Sinn-Zong Lin and Dr. Tsung-Lang Chiu from Tzu Chi General Hospital and Dr. Sin-I Ma, Dr. Yuan-Hao Chen, Dr. Tung-Yuan Hong, and Dr. Wei-Hsiu Liu from Tri-Service General Hospital as the principal investigators. The Phase I human trial study aimed to treat patients with high grade recurrent glioblastoma multiforme using brain-targeted drugs implanted into the brain. With the completion of this trial, Everfront Biotech Inc. has made significant progress towards its goal of developing drugs to treat malignant brain tumors.
Collaboration between Lotus Pharma, Tzu Chi Hospital and Everfront Biotech for Clinical Trials of New Drugs for Glioblastoma Multiforme in June
Date: 2017/5/22
Five years ago, Everfront Biotech Inc. acquired the key technology from Hualien Tzu Chi Hospital and National Dong Hwa University to develop Cerebraca® Wafer, a targeted anti-cancer drug for the treatment of glioblastoma multiforme. Cerebraca® Wafer slowly releases and diffuses into the surrounding brain tissue, eliminating residual tumor cells that were not completely removed during surgery. By inhibiting the DNA repair gene MGMT, which causes resistance to Temozolomide, malignant cells that were resistant to Temozolomide can be killed again. Currently, Cerebraca® Wafer has been granted patents in Taiwan, China, the United States, Japan, and the European Union. Since August 2016, it has obtained clinical trial approval from the US Food and Drug Administration (FDA) and Taiwan Food and Drug Administration (TFDA). In January of this year, Everfront Biotech Inc. signed a contract with Hualien Tzu Chi Hospital to conduct Phase I trial….
Cerebraca® wafer, a Locally Developed Targeted Drug, Brings New Hopes for the Treatment of Glioblastoma Multiforme. Everfront Biotech and Tzu Chi Hospital Have Signed a Contract to Collaborate and Embark on a New Journey
Date: 2017/1/26
On January 26th, Everfront Biotech Inc. signed a letter of intent with Hualien Tzu Chi Hospital to commission the hospital to conduct the Phase I/IIa trial of the targeted new drug Cerebraca® Wafer for the treatment of glioblastoma multiforme. The clinical trial aims to test the safety and effectiveness of the new drug in humans and hopes to help patients with malignant brain tumors in the future.
At 10:00 am on January 26th, Mrs. Pei-Wen Chou, chairman of Everfront Biotech Inc., and Dr. Shinn-Zong Lin, Superintendent of Hualien Tzu Chi Hospital, signed the letter of intent at the hospital.
